Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Universite de Montreal
Deal Size : Undisclosed
Deal Type : Collaboration
IRICoR, UdeM, IRIC and Valence Discovery collaborate to design novel drug candidates
Details : The collaboration builds on research from the team of Dr. Daniel Levesque at UdeM, and focuses on the design of highly selective modulators of the Nur77/RXR nuclear receptor complex, a promising new pharmacological target for movement disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 03, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Universite de Montreal
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ECT-001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : ExCellThera
Deal Size : Undisclosed
Deal Type : Funding
IRICoR Makes Additional Investment in ExCellThera
Details : IRICoR's investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine for a Phase 1 clinical trial using its ECT-001, for the treatment of severe sickl...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : ECT-001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : ExCellThera
Deal Size : Undisclosed
Deal Type : Funding